Nuclidium raises €84.0M Series B round
10 July 2025· Basel, Switzerland· health, biotech, radiopharmaceuticals, theranostics, b2b, deep_hardware
The proceeds will be used to advance the clinical development of NUCLIDIUM's Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline across multiple oncology indications. In parallel, the company will expand its production and manufacturing capabilities through a global production network, and expand its international team while strengthening collaborations with hospitals and academic centers in Europe and North America.
Investors
LeadKurma Growth Opportunities Fund
Also participating
Bayern KapitalEurazeoNRW.BankAngelini VenturesWellington PartnersNeva SGR (Intesa Sanpaolo Group)DeepTech & Climate Fonds (DTCF)Vives PartnersHighLight Capital
About Nuclidium
Stage
Series B
Headquarters
Basel, Switzerland
Founded
2017
Team Size
6–20
Sectors
healthbiotechradiopharmaceuticalstheranosticsb2bdeep_hardware